Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome

INTRODUCTION: Treatment of hypercholesterolemia in refractory nephrotic syndrome remains a therapeutic challenge. There is not enough evidence supporting the efficacy of statins, and these drugs can be associated with an increased incidence of adverse effects. Herein we summarize our clinical experi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jatem, Elias, Lima, Joan, Montoro, Bruno, Torres-Bondia, Francisco, Segarra, Alfons
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783565/
https://www.ncbi.nlm.nih.gov/pubmed/33426389
http://dx.doi.org/10.1016/j.ekir.2020.09.046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783565/
https://www.ncbi.nlm.nih.gov/pubmed/33426389
http://dx.doi.org/10.1016/j.ekir.2020.09.046

Ejemplares similares